Related Experiment Video

Updated: Jun 4, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Therapeutic inhibition of angiogenesis

H T Zhang1, R Bicknell

  • 1Molecular Angiogenesis Laboratory,Imperial Cancer Research Fund;Institute of Molecular Medicine, University of Oxford; John Radcliffe Hospital, Oxford, UK.

Methods in Molecular Medicine
|February 23, 2011
PubMed

Insights

Antiangiogenic therapy, a strategy targeting abnormal blood vessel growth, shows promise for treating various conditions, including infantile hemangioma and vascular tumors. This approach is being explored for numerous pathologies involving excessive or insufficient angiogenesis.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Antiangiogenesis has been investigated as a therapeutic strategy for decades.
  • It is now recognized as a promising approach for diseases characterized by uncontrolled vascular proliferation.
  • Therapeutic benefits have been observed in infantile hemangioma, pulmonary hemangiomatosis, and certain vascular tumors.

Purpose of the Study:

  • To review the therapeutic potential of antiangiogenesis.
  • To highlight pathologies that could benefit from modulating angiogenesis.
  • To underscore the established and emerging applications of antiangiogenic therapies.

Main Methods:

  • Review of existing literature on antiangiogenesis.
  • Analysis of pathologies associated with aberrant angiogenesis (excess or insufficiency).
  • Compilation of therapeutic successes in specific vascular conditions.

Main Results:

  • Antiangiogenic therapy has demonstrated efficacy in treating infantile hemangioma and vascular tumors.
  • A wide range of pathologies, including arthritis, cancer, and macular degeneration, are potential targets for antiangiogenic interventions.
  • The table categorizes conditions based on whether they involve excess or insufficient angiogenesis.

Conclusions:

  • Antiangiogenesis is a validated therapeutic strategy with proven benefits in specific vascular disorders.
  • Further research and application in diverse pathologies involving angiogenesis dysregulation are warranted.
  • Modulating angiogenesis offers a promising avenue for treating numerous diseases beyond cancer.

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Rat Mesentery Angiogenesis Assay18:30

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...